Roche's Avastin-Xeloda combo extends breast cancer survival; Genzyme sees faster rollouts coming in China;

@FiercePharma: ICYMI yesterday: Overseas limits on J&J's Olysio use might signal trouble back home. Item | More | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

> Roche ($RHHBY) said its cancer drug Avastin, when combined with its chemotherapy Xeloda, helped women with HER2-negative breast cancer live longer than those treated with Avastin alone. Report

> Genzyme CEO David Meeker says it expects to roll out new drugs in China at a faster pace in the future because the country's understanding of rare diseases has grown. Report

> Valeant Pharmaceuticals ($VRX) brought another representative of top shareholder ValueAct, Jeffrey Ubben, onto its board to replace the departed Mason Morfit. Report

> MannKind ($MNKD) said its Afrezza marketing deal with Sanofi ($SNY) has closed, putting the smaller company in line for a $150 million up-front payment. Release

> Bridgewater, NJ-based Amneal Pharmaceuticals said it would expand its sales and distribution center in Kentucky. Report

Medical Device News

@FierceMedDev: NIH launches study of 'exceptional responders' to cancer therapies. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Titan Pharma trial of implant for addicts on track. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: 3-D printed blood vessels? Check. On to the 3-D printed kidneys, say researchers at Harvard. More from MIT Technology Review | Follow @EmilyWFierce

> At least 23 digital health apps clear FDA this year. Item

> Court rules that Boston Scientific owes inventor of pacemaker $309M. Report

Biotech News

@FierceBiotech: VentiRx banks $50M as it ramps up immuno-oncology research efforts in Seattle. Report | Follow @FierceBiotech

@JohnCFierce: Adaptimmune gathers $104M to fuel hot immuno-oncology tech race - TCRs/CAR-T. More | Follow @JohnCFierce

@DamianFierce: Here's the official Kadmon release on the Waksal swap, replete with semi-acknowledgement of IPO plot. Release | Follow @DamianFierce

@EmilyMFierce: This on misses the mark in so many ways and lacks a basic understanding of drug development. Article | Follow @EmilyMFierce

> Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet. News

> Valeant talks up the billion-dollar potential of its Phase III eye drug. Story

> Novartis' blockbuster hopeful scores a win in psoriatic arthritis. Article

Vaccines News

> Inovio joins Ebola fight while WHO says a vaccine could be ready by year's end. Story

> CureVac inks lung cancer vaccine deal with Boehringer for up to $600M. Report

> U.K. panel under pressure to extend use of Merck's Gardasil to boys. Article

> Pharmacies continue push to lower barriers to seasonal flu vaccination. Report

> Accidental poliovirus dump adds to GSK's production woes. More

Pharma Manufacturing News

> IGI jumps into sterile injectable biz with $9.5M deal with AstraZeneca. More

> Report: 'Green' manufacturing needed to save money as well as the environment. Item

> Sanofi expands production at Merial plant in Brazil. More

> Alkermes manufacturing technology key to Acorda buyout of Civitas. Article

> Impax settles securities suit tied to its manufacturing issues. Story

And Finally... The rate of growth in diabetes in the U.S. appears to have plateaued. Report (sub. req.)

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.